Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors

Moustapha Kassem, Steven A. Harris, Thomas C. Spelsberg, B. Lawrence Riggs

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Some studies suggest that estrogen acts on bone by decreasing the production of interleukin-6 (IL-6), a cytokine that increases bone resorption, by osteoblasts or bone marrow cells. However, other studies have not confirmed this, possibly because of a low and variable number of estrogen receptors (ER) in the model systems used. Thus, we employed a recently developed human fetal osteoblast cell line with high levels of ER. Treatment (n = 4 experiments) with 0.01 to 10 nM of 17β-estradiol had no effect on the constitutive production of IL-6. However, stimulated production, induced by treatment with IL-1β plus tumor necrosis factor-α (TNF-α), was reduced in a dose-dependent manner to 74 ± 3% (mean ± SEM) of control (p < 0.01). This response was blocked by cotreatment with the type II antiestrogeu ICI 182,780. Treatment with hydrocortisone (1 μM), a known inhibitor of IL-6 production in many cell types, reduced IL-6 production to 17 ± 1% of control (p < 0.001). As assessed by Northern analysis, treatment (n = 3 experiments) with 0.01-10 nM of 17β-estradiol decreased steady-state levels of IL-6 mRNA in a dose-dependent manner. These data support the hypothesis that at least part of the antiresorptive action of estrogen in humans is mediated by decreased production of IL-6 by osteoblastic cells.

Original languageEnglish (US)
Pages (from-to)193-199
Number of pages7
JournalJournal of Bone and Mineral Research
Volume11
Issue number2
StatePublished - Feb 1996

Fingerprint

Estrogen Receptors
Interleukin-6
Estrogens
Gene Expression
Cell Line
Osteoblasts
Estradiol
Bone and Bones
Bone Resorption
Interleukin-1
Bone Marrow Cells
Hydrocortisone
Tumor Necrosis Factor-alpha
Cytokines
Messenger RNA

ASJC Scopus subject areas

  • Surgery

Cite this

Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors. / Kassem, Moustapha; Harris, Steven A.; Spelsberg, Thomas C.; Riggs, B. Lawrence.

In: Journal of Bone and Mineral Research, Vol. 11, No. 2, 02.1996, p. 193-199.

Research output: Contribution to journalArticle

Kassem, Moustapha ; Harris, Steven A. ; Spelsberg, Thomas C. ; Riggs, B. Lawrence. / Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors. In: Journal of Bone and Mineral Research. 1996 ; Vol. 11, No. 2. pp. 193-199.
@article{49769a8c9f9c4babab91c350af7bfb85,
title = "Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors",
abstract = "Some studies suggest that estrogen acts on bone by decreasing the production of interleukin-6 (IL-6), a cytokine that increases bone resorption, by osteoblasts or bone marrow cells. However, other studies have not confirmed this, possibly because of a low and variable number of estrogen receptors (ER) in the model systems used. Thus, we employed a recently developed human fetal osteoblast cell line with high levels of ER. Treatment (n = 4 experiments) with 0.01 to 10 nM of 17β-estradiol had no effect on the constitutive production of IL-6. However, stimulated production, induced by treatment with IL-1β plus tumor necrosis factor-α (TNF-α), was reduced in a dose-dependent manner to 74 ± 3{\%} (mean ± SEM) of control (p < 0.01). This response was blocked by cotreatment with the type II antiestrogeu ICI 182,780. Treatment with hydrocortisone (1 μM), a known inhibitor of IL-6 production in many cell types, reduced IL-6 production to 17 ± 1{\%} of control (p < 0.001). As assessed by Northern analysis, treatment (n = 3 experiments) with 0.01-10 nM of 17β-estradiol decreased steady-state levels of IL-6 mRNA in a dose-dependent manner. These data support the hypothesis that at least part of the antiresorptive action of estrogen in humans is mediated by decreased production of IL-6 by osteoblastic cells.",
author = "Moustapha Kassem and Harris, {Steven A.} and Spelsberg, {Thomas C.} and Riggs, {B. Lawrence}",
year = "1996",
month = "2",
language = "English (US)",
volume = "11",
pages = "193--199",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors

AU - Kassem, Moustapha

AU - Harris, Steven A.

AU - Spelsberg, Thomas C.

AU - Riggs, B. Lawrence

PY - 1996/2

Y1 - 1996/2

N2 - Some studies suggest that estrogen acts on bone by decreasing the production of interleukin-6 (IL-6), a cytokine that increases bone resorption, by osteoblasts or bone marrow cells. However, other studies have not confirmed this, possibly because of a low and variable number of estrogen receptors (ER) in the model systems used. Thus, we employed a recently developed human fetal osteoblast cell line with high levels of ER. Treatment (n = 4 experiments) with 0.01 to 10 nM of 17β-estradiol had no effect on the constitutive production of IL-6. However, stimulated production, induced by treatment with IL-1β plus tumor necrosis factor-α (TNF-α), was reduced in a dose-dependent manner to 74 ± 3% (mean ± SEM) of control (p < 0.01). This response was blocked by cotreatment with the type II antiestrogeu ICI 182,780. Treatment with hydrocortisone (1 μM), a known inhibitor of IL-6 production in many cell types, reduced IL-6 production to 17 ± 1% of control (p < 0.001). As assessed by Northern analysis, treatment (n = 3 experiments) with 0.01-10 nM of 17β-estradiol decreased steady-state levels of IL-6 mRNA in a dose-dependent manner. These data support the hypothesis that at least part of the antiresorptive action of estrogen in humans is mediated by decreased production of IL-6 by osteoblastic cells.

AB - Some studies suggest that estrogen acts on bone by decreasing the production of interleukin-6 (IL-6), a cytokine that increases bone resorption, by osteoblasts or bone marrow cells. However, other studies have not confirmed this, possibly because of a low and variable number of estrogen receptors (ER) in the model systems used. Thus, we employed a recently developed human fetal osteoblast cell line with high levels of ER. Treatment (n = 4 experiments) with 0.01 to 10 nM of 17β-estradiol had no effect on the constitutive production of IL-6. However, stimulated production, induced by treatment with IL-1β plus tumor necrosis factor-α (TNF-α), was reduced in a dose-dependent manner to 74 ± 3% (mean ± SEM) of control (p < 0.01). This response was blocked by cotreatment with the type II antiestrogeu ICI 182,780. Treatment with hydrocortisone (1 μM), a known inhibitor of IL-6 production in many cell types, reduced IL-6 production to 17 ± 1% of control (p < 0.001). As assessed by Northern analysis, treatment (n = 3 experiments) with 0.01-10 nM of 17β-estradiol decreased steady-state levels of IL-6 mRNA in a dose-dependent manner. These data support the hypothesis that at least part of the antiresorptive action of estrogen in humans is mediated by decreased production of IL-6 by osteoblastic cells.

UR - http://www.scopus.com/inward/record.url?scp=0030020568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030020568&partnerID=8YFLogxK

M3 - Article

C2 - 8822343

AN - SCOPUS:0030020568

VL - 11

SP - 193

EP - 199

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 2

ER -